Guggenheim Capital LLC Has $3.48 Million Stock Holdings in Guardant Health, Inc. (NASDAQ:GH)

Guggenheim Capital LLC decreased its stake in Guardant Health, Inc. (NASDAQ:GH - Free Report) by 9.4% in the fourth quarter, according to its most recent filing with the Securities & Exchange Commission. The firm owned 113,850 shares of the company's stock after selling 11,830 shares during the quarter. Guggenheim Capital LLC owned 0.09% of Guardant Health worth $3,478,000 as of its most recent filing with the Securities & Exchange Commission.

Other institutional investors have also recently bought and sold shares of the company. R Squared Ltd acquired a new position in Guardant Health in the 4th quarter valued at approximately $26,000. SBI Securities Co. Ltd. acquired a new position in shares of Guardant Health in the fourth quarter worth $43,000. Kimelman & Baird LLC purchased a new stake in shares of Guardant Health during the fourth quarter worth $58,000. Quantbot Technologies LP acquired a new stake in Guardant Health during the fourth quarter valued at $80,000. Finally, Jones Financial Companies Lllp grew its stake in Guardant Health by 43.5% in the fourth quarter. Jones Financial Companies Lllp now owns 2,696 shares of the company's stock valued at $82,000 after purchasing an additional 817 shares in the last quarter. Hedge funds and other institutional investors own 92.60% of the company's stock.

Wall Street Analyst Weigh In

Several equities research analysts have recently issued reports on GH shares. Canaccord Genuity Group boosted their price target on Guardant Health from $42.00 to $60.00 and gave the company a "buy" rating in a research note on Monday, February 24th. Piper Sandler boosted their target price on shares of Guardant Health from $34.00 to $50.00 and gave the stock an "overweight" rating in a research report on Wednesday, February 26th. Stephens restated an "overweight" rating and set a $55.00 price target on shares of Guardant Health in a report on Wednesday, March 26th. JPMorgan Chase & Co. upped their price objective on shares of Guardant Health from $50.00 to $55.00 and gave the stock an "overweight" rating in a report on Friday, February 21st. Finally, Mizuho assumed coverage on Guardant Health in a research report on Thursday, April 10th. They issued an "outperform" rating and a $55.00 price target for the company. Twenty analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company's stock. According to data from MarketBeat, the stock presently has an average rating of "Buy" and a consensus target price of $49.00.

Guardant Health Trading Up 4.4 %

GH traded up $1.93 on Wednesday, hitting $45.73. 2,028,114 shares of the stock traded hands, compared to its average volume of 2,139,978. The business has a fifty day moving average price of $43.43 and a two-hundred day moving average price of $36.76. The firm has a market capitalization of $5.64 billion, a PE ratio of -12.85 and a beta of 1.45. Guardant Health, Inc. has a 52 week low of $16.77 and a 52 week high of $50.89.

Guardant Health (NASDAQ:GH - Get Free Report) last issued its earnings results on Thursday, February 20th. The company reported ($0.90) EPS for the quarter, missing analysts' consensus estimates of ($0.75) by ($0.15). Guardant Health had a negative net margin of 59.05% and a negative return on equity of 19,157.20%. The firm had revenue of $201.81 million during the quarter, compared to analyst estimates of $192.50 million. On average, equities research analysts forecast that Guardant Health, Inc. will post -2.9 EPS for the current fiscal year.

Guardant Health Company Profile

Guardant Health, Inc, a precision oncology company, provides blood and tissue tests, data sets, and analytics in the United States and internationally. The company provides Guardant360; Guardant360 LDT; Guardant360 CDx Test; Guardant360 Response Test; Guardant360 TissueNext Test; GuardantINFINITY Test; GuardantConnect, an integrated software-based solution designed for clinical and biopharmaceutical customers to connect patients tested with assays with actionable alterations with potentially relevant clinical studies; GuardantOMNI Test for advanced stage cancer; and GuardantINFORM, an in-silico research platform for tumor evolution and treatment resistance across various biomarker-driven cancers.